AIM — AIM ImmunoTech Inc.

Is AIM overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of August 19, 2026

AIM ImmunoTech Inc. (AIM) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $0.23. The rating moved from Neutral to Oversold on August 12, 2026.

See all oversold Healthcare stocks →

AI analysis

AIM ImmunoTech is a small, clinical-stage immunotherapy company with outcome-driven valuation and limited near-term revenues. The investment case is dependent on positive clinical/regulatory catalysts or meaningful partnership/licensing deals; absent those, cash burn and dilution are the dominant near-term concerns. Market perception is likely to remain sensitive to trial updates and financing news, and the company is exposed to high volatility and execution risk.

Key factors

  • Small-cap clinical-stage immunotherapy developer with limited or irregular revenue streams; financial sustainability depends on financing, partnerships, or milestone receipts.
  • Business model and near-term value are highly binary and tied to clinical data, regulatory interactions, and potential licensing or commercialization deals.
  • Historically thin trading liquidity and low share price increase susceptibility to volatility and wide intraday moves.
  • Sector environment shows demand for biologics/CDMO and increased policy focus on access, which could create downstream opportunities but does not directly mitigate company-level clinical and financing risk.
  • Lack of recent, material public filings or social sentiment data in the provided inputs increases uncertainty about short-term operational runway and catalyst timing.
  • Macro risk-off moves or rising rates can disproportionately pressure penny/clinical-stage stocks due to discounting of long-dated, uncertain upside.

Risks

  • Clinical trial failure or delays that eliminate expected value inflection points.
  • Insufficient cash runway leading to dilution via equity raises or dilutive financings.
  • Regulatory setbacks or protracted review timelines that push commercialization far into the future.
  • Thin liquidity and low market capitalization causing exaggerated price moves and limited ability for large investors to enter or exit positions.
  • Negative counterparties or partner decisions (withdrawn collaboration or lack of licensing interest) reducing commercialization prospects.
  • Adverse news/rumor-driven sentiment on social platforms or in OTC markets amplifying downside pressure.

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for AIM — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.